Hematology NewsCRB-410 update: Multiple myeloma response rates remain high with bb2121 CAR T-cell therapyDecember 15, 2017Multiple MyelomaImmuno-oncology
Hematology NewsDaratumumab plus VMP boosts PFS, MRD-negativity in de novo myelomaDecember 12, 2017Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology NewsVIDEO: Daratumumab gives kick to standard first-line myeloma therapyDecember 12, 2017Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology NewsActivating the Immune System to Treat Multiple MyelomaDecember 11, 2017Multiple Myeloma
Hematology NewsAnti-BCMA CAR T-cell therapy being fast tracked at FDADecember 6, 2017Multiple Myeloma
Hematology NewsGSI may boost BCMA CAR T-cell therapy efficacy in myelomaNovember 27, 2017Multiple Myeloma
Hematology TimesTeam identifies genetic differences between MM patientsNovember 27, 2017Multiple Myeloma
Hematology NewsCAR T-cells gain ground against hematologic cancersNovember 22, 2017Aggressive LymphomasMultiple MyelomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Oncology PracticeLate-breaking abstracts highlight treatment advances in CLL, myeloma, and moreNovember 22, 2017ThrombosisCLLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple Myeloma
